**RESULTS**

**Efficacy**
Participants with clinical success defined as achieving IGA score of clear (0) or almost clear (1) at week 8 of treatment discontinuation were 180 (52.8%) of 343 participants who achieved IGAxBSA-75 at or before week 12. In the open-label study, rates of these skin reactions were absent in all participants with moderate-to-severe itch, dryness, and stinging/burning who achieved IGAxBSA-75 at or before week 12.

**Safety**
Across all studies, rates of skin atrophy, striae, telangiectasias, and folliculitis were low. At week 12, 52% of participants who achieved IGAxBSA-75 at or before week 12 had no treatment discontinuation.

**CONCLUSIONS**
- HP/TAZ was associated with long-term skin clearance in patients who achieved clinically meaningful improvement in psoriasis lesions, as measured by IGAxBSA-75.
- Clinically meaningful improvement in psoriasis lesions was also associated with decreased signs and symptoms (itch, dryness, and burning/stinging) and posttreatment maintenance of those improvements.

---

Andrew Alexis, Jr, James Del Rosso, Tina Bhutani, Kim Papp, Abby Jacobson
Department of Dermatology, Weill Cornell Medical College, New York, NY; JDR Dermatology Research/Theodore Dermatology, Las Vegas, NV; UCIIP Pсорiasis and Skin Treatment Center, San Francisco, CA; Probiotics Medical Research and K. Papp Clinical Research, Waterloo, Ontario, Canada; Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ.